恶性中心气道梗阻治疗性支气管镜后的长期质量调整生存
这项前瞻性观察研究纳入102例因恶性中心气道梗阻接受治疗性支气管镜的患者,90%获得部分或完全技术成功。术后第7天呼吸困难(平均ΔBorg=-1.8)和健康相关生活质量(平均Δutility=+0.047 utiles)均改善并长期维持,中位质量调整生存为109个质量调整生命日(QALDs)。
要点
- 治疗性支气管镜技术成功率高,可缓解恶性中心气道梗阻。
- 术后呼吸困难与生活质量改善可长期维持。
- 中位质量调整生存为109个质量调整生命日(QALDs)。
核心结论
- 治疗性支气管镜较基线改善健康相关生活质量,使生存期间每日生活质量约改善5.8%。
- 在经仔细选择的患者中,该操作的获益-风险特征非常有利。
研究设计与样本
- 前瞻性观察研究,连续纳入接受治疗性支气管镜的恶性中心气道梗阻患者。
- 共102例患者,术后1周及此后每月随访至死亡。
主要发现
- 90%的患者获得部分或完全技术成功(即解剖梗阻缓解)。
- 术后第7天呼吸困难改善:平均ΔBorg-day-7=-1.8(95%CI -2.2至-1.3,p<0.0001)。
- 术后第7天健康相关生活质量改善:平均Δutility-day-7=+0.047 utiles(95%CI +0.023至+0.071,p=0.0002)。
- 呼吸困难和生活质量改善长期维持;术后每日生活质量较术前基线改善:平均Δutility-long-term=+0.036 utiles(95%CI +0.014至+0.057,p=0.002)。
- 中位质量调整生存为109个质量调整生命日(QALDs)(95%CI 74至201 QALDs)。
关键数值与推荐
- 技术成功定义为解剖梗阻缓解,部分或完全技术成功见于90%的患者。
- 与较长质量调整生存相关的因素包括:较好功能状态、未经治疗的肿瘤、腔内病变、较轻呼吸困难、从诊断到支气管镜时间较短、无心脏病、支气管镜扩张及接受化疗。
临床怎么用
- 对经选择的恶性中心气道梗阻患者,治疗性支气管镜可改善呼吸困难与生活质量,并延长质量调整生存。
- 评估获益时需结合功能状态、肿瘤治疗史、病变类型、呼吸困难程度、合并心脏病及后续化疗等因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While therapeutic bronchoscopy has been used to treat malignant central (CAO) airway obstruction for >25 years, there are no studies quantifying the impact of therapeutic bronchoscopy on long-term quality-adjusted survival. METHODS: We conducted a prospective observational study of consecutive patients undergoing therapeutic bronchoscopy for CAO. Patients had follow-up at 1 week and monthly thereafter until death. Outcomes included technical success (ie, relief of anatomic obstruction), dyspnoea, health-related quality of life (HRQOL) and quality-adjusted survival. RESULTS: Therapeutic bronchoscopy was performed on 102 patients with malignant CAO. Partial or complete technical success was achieved in 90% of patients. At 7 days postbronchoscopy, dyspnoea improved (mean ∆Borg-day-7=-1.8, 95% CI -2.2 to -1.3, p<0.0001) and HRQOL improved (median prebronchoscopy 0.618 utiles, 25%-75% IQR 0.569 to 0.699, mean ∆utility-day-7+0.047 utiles, 95% CI +0.023 to 0.071, p=0.0002). Improvements in dyspnoea and HRQOL were maintained long-term. Compared with the prebronchoscopy baseline, HRQOL per day of life postbronchoscopy improved (mean ∆utility-long-term+0.036 utiles, 95% CI +0.014 to 0.057, p=0.002). Median quality-adjusted survival was 109 quality-adjusted life-days (QALDs) (95% CI 74 to 201 QALDs). Factors associated with longer quality-adjusted survival included better functional status, treatment-naïve tumour, endobronchial disease, less dyspnoea, shorter time from diagnosis to bronchoscopy, absence of cardiac disease, bronchoscopic dilation and receiving chemotherapy. CONCLUSIONS: Therapeutic bronchoscopy improves HRQOL as compared with baseline, resulting in approximately a 5.8% improvement in HRQOL per day of life. The risk-benefit profile in these carefully selected patients was very favourable. TRIAL REGISTRATION NUMBER: Results; NCT03326570.
引用
- Ong P, Grosu HB, Debiane L, et al. Long-term quality-adjusted survival following therapeutic bronchoscopy for malignant central airway obstruction. Thorax. 2018. PMID: 30254139. doi:10.1136/thoraxjnl-2018-211521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。